News brief­ing: Pfiz­er on track to ear­ly '22 piv­otal read­out on he­mo­phil­ia A; Co­di­ak scales back IPO ex­pec­ta­tions

Pfiz­er and Sang­amo have dosed their first pa­tient in the Phase III gene ther­a­py tri­al of giroc­toco­gene fitel­par­vovec (SB-525) for he­mo­phil­ia A. Re­searchers will be fol­low­ing the ex­pe­ri­ences of pa­tients for 12 months af­ter dose, check­ing on safe­ty, ef­fi­ca­cy and dura­bil­i­ty. The move comes on the heels of a ma­jor set­back at ri­val Bio­Marin, which re­ceived a re­jec­tion let­ter from the FDA, which de­mand­ed more proof of dura­bil­i­ty — a sore point among some of the an­a­lysts track­ing the pro­gram.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER